New drug duo aims to outsmart resistant lung cancer
NCT ID NCT07486648
Summary
This study is testing whether adding a new drug called capivasertib to a standard lung cancer drug (osimertinib) can help control advanced non-small cell lung cancer that has specific genetic changes and has started growing again after initial treatment. It will involve about 53 adults. The first part of the study aims to find a safe combined dose, and the second part will see how well the combination works at shrinking or controlling tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.